A novel vaginal pH regulator: results from the phase 3 AMPOWER contraception clinical trial
Contraception: X · 2020 · 2 · 100031
DOI: 10.1016/j.conx.2020.100031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Contraception: X, 2020. Verfasst von Michael A Thomas und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Cincinnati, 231 Albert Sabin Way, Cincinnati, OH, 45219, USA. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Evofem Biosciences, Inc.
Abstract (Originalsprache)
OBJECTIVE: The objective was to evaluate the contraceptive effectiveness, safety, and acceptability of a novel vaginal pH regulator over seven cycles of use. STUDY DESIGN: A single-arm, open-label, phase 3 study was conducted across 112 sites in the United States in sexually active 18-35-year-old women at risk of pregnancy. Women administered the study treatment ≤ 1 h before each episode of intercourse. Women recorded use of study drug, coital information, and any symptoms experienced in electronic diaries. The primary outcome was the seven-cycle cumulative pregnancy rate as calculated using the Kaplan-Meier methodology; secondary outcomes included safety. Overall satisfaction was assessed via written questionnaires. RESULTS: A total of 1384 women were enrolled in the study from July 2017 to November 2018. Mean age was 27.7 ± 4.4 years; most women were white (69.0%). The seven-cycle cumulative pregnancy percentage was 13.7% [95% confidence interval (CI): 10.0%-17.5%], meeting the prespecified primary endpoint of having the upper bound 95% CI ≤ 21%. Most common adverse events (AEs) occurring in ≥ 2% of women were vulvovaginal burning sensation, vulvovaginal pruritus, urinary tract infection, vulvovaginal pain, mycotic infection, bacterial vaginosis, and nasopharyngitis. Of 1330 women who used the study drug at least once, fewer than 2% of women discontinued due to any AEs, and 80% of women reported being "very satisfied" or "satisfied" with study treatment. CONCLUSIONS: In this phase 3 study, the novel vaginal pH regulator demonstrated 86.3% contraceptive effectiveness, was safe and well tolerated, and was highly acceptable. IMPLICATIONS: This novel vaginal pH regulator is a safe, nonhormonal, woman-controlled method of contraception that expands women's options.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Cincinnati, 231 Albert Sabin Way, Cincinnati, OH, 45219, USA.
- Adams Patterson Gynecology & Obstetrics, 1727 Kirby Parkway, Memphis, TN, 38210, USA.
- Maximos Obstetrics and Gynecology, 651 Egret Bay Boulevard, League City, TX, 77573, USA.
- Evofem Biosciences, Inc., 12400 High Bluff Drive, Suite 600, San Diego, CA, 92130, USA.
- Health Decisions, 2510 Meridian Parkway, Durham, NC, 27713, USA.
Förderung
- Evofem Biosciences, Inc
Zitieren
APA
Thomas, M. A., Chappell, B. T., Maximos, B., Culwell, K. R., Dart, C., & Howard, B. (2020). A novel vaginal pH regulator: results from the phase 3 AMPOWER contraception clinical trial. Contraception: X, 2, 100031. https://doi.org/10.1016/j.conx.2020.100031
Vancouver
Thomas MA, Chappell BT, Maximos B, Culwell KR, Dart C, Howard B. A novel vaginal pH regulator: results from the phase 3 AMPOWER contraception clinical trial. Contraception: X. 2020;2:100031. doi:10.1016/j.conx.2020.100031
BibTeX
@article{Thomas2020,
author = {Thomas, Michael A and Chappell, B Todd and Maximos, Bassem and Culwell, Kelly R and Dart, Clint and Howard, Brandon},
title = {A novel vaginal pH regulator: results from the phase 3 AMPOWER contraception clinical trial},
journal = {Contraception: X},
year = {2020},
volume = {2},
pages = {100031},
doi = {10.1016/j.conx.2020.100031}
}
EUVIMED